3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
97
Leukemia, Lymphocytic, Chronic, B-Cell
88
Lymphoma, Follicular
81
Lymphoma
62
Lymphoma, Mantle-Cell
59
Lymphoma, B-Cell, Marginal Zone
47
Lymphoma, Non-Hodgkin
46
Recurrence
35
Lymphoma, B-Cell
24
Leukemia
20
Waldenstrom Macroglobulinemia
18
Hodgkin Disease
18
Lymphoma, T-Cell, Peripheral
16
Burkitt Lymphoma
14
Lymphoma, T-Cell, Cutaneous
12
Lymphoma, T-Cell
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Sezary Syndrome
10
Mycosis Fungoides
10
Multiple Myeloma
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Large-Cell, Anaplastic
9
Immunoblastic Lymphadenopathy
8
Lymphoma, Large-Cell, Immunoblastic
7
Intraocular Lymphoma
7
Neoplasms
6
Lymphoma, Extranodal NK-T-Cell
6
Leukemia, B-Cell
6
Leukemia, Hairy Cell
5
Leukemia-Lymphoma, Adult T-Cell
4
Interventions
Cyclophosphamide
13
fludarabine
9
fludarabine phosphate
7
Bendamustine Hydrochloride
5
Rituximab
4
Busulfan
4
ibrutinib
3
Tacrolimus
3
Mycophenolic Acid
3
Melphalan
3
Bortezomib
3
AP 1903 reagent
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
pembrolizumab
1
ibritumomab tiuxetan
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immune System Diseases
×
Lenalidomide
×
Lymphoid
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts